COVID-19-induced sarcopenia and physical deconditioning may require reassessment of surgical risk for patients with cancer

Patrick Casey, Yeng Ang, Javed Sultan, Patrick Casey, Yeng Ang, Javed Sultan

Abstract

Background: The long-term physiological consequences of SARS-CoV-2 (severe acute respiratory syndrome coronavirus) infection are not known. The ability of COVID-19 to cause chronic illness, sarcopenia, and physical deconditioning may be underestimated and go beyond the anticipated respiratory sequelae. Myalgia, lethargy, and anorexia are common symptoms even in mild to moderate cases and have the potential to exacerbate frailty. How this impacts on risk-stratification for patients requiring surgery for time-critical conditions, such as malignancy, requires further urgent investigation.

Main body: The deleterious effect of sarcopenia and poor physical capacity are well recognised in cancer surgery. This review commentary highlights current evidence which suggests skeletal muscle as an under recognised cause of COVID-19-related functional deconditioning. The mechanisms behind this are via direct (viral induced myositis, nutritional decline, cytokine-mediated myopathy) and indirect mechanisms (social isolation, inactivity, and psychological consequences).

Conclusion: Further mechanistic research is required to explore the processes behind the deconditioning effects of SARS-CoV-2 infection and how this impacts on treatment of malignant disease.

Keywords: COVID-19; Frailty; Functional deconditioning; Prehabilitation; SARS-CoV-2; Sarcopenia.

Conflict of interest statement

The authors have no competing interests to declare.

Figures

Fig. 1
Fig. 1
Schematic of proposed mechanisms causing deterioration in physical function and sarcopenia in patients requiring cancer surgery. Multimodal prehabilitation for COVID survivors may be required to overcome these factors. NACRx, neoadjuvant chemoradiotherapy

References

    1. Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026. doi: 10.1136/bmj.m3026.
    1. Nasiri MJ, Haddadi S, Tahvildari A, et al. COVID-19 clinical characteristics, and sex-specific risk of mortality: Systematic Review and Meta-analysis. medRxiv. 2020:2020.03.24.20042903. 10.1101/2020.03.24.20042903.
    1. Heydari K, Rismantab S, Shamshirian A, et al. Clinical and paraclinical characteristics of covid-19 patients: a systematic review and meta-analysis. medRxiv. 2020:2020.03.26.20044057. 10.1101/2020.03.26.20044057.
    1. Garner P. Paul Garner: For 7 weeks I have been through a roller coaster of ill health, extreme emotions, and utter exhaustion: BMJ Publishing Group; 2020. .
    1. Arnold DT, Hamilton FW, Milne A, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up; results from a prospective UK cohort. medRxiv. 2020:2020.08.12.20173526. 10.1101/2020.08.12.20173526.
    1. Carfì A, Bernabei R, Landi F. Group for the GAC-19 P-ACS. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603–605. doi: 10.1001/jama.2020.12603.
    1. Pipek LZ, Baptista CG, Nascimento RFV, et al. The impact of properly diagnosed sarcopenia on postoperative outcomes after gastrointestinal surgery: A systematic review and meta-analysis. PLoS One. 2020;15(8):e0237740. doi: 10.1371/journal.pone.0237740.
    1. Tu H, Tu S, Gao S, Shao A, Sheng J. Current epidemiological and clinical features of COVID-19; a global perspective from China. J Infect. 2020;81(1):1–9. doi: 10.1016/j.jinf.2020.04.011.
    1. Lippi G, Wong J, Henry BM. Myalgia may not be associated with severity of coronavirus disease 2019 (COVID-19) World J Emerg Med. 2020;11(3):193–194. doi: 10.5847/wjem.j.1920-8642.2020.03.013.
    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5.
    1. Li J. Rehabilitation management of patients with COVID-19: lessons learned from the first experience in China. Eur J Phys Rehabil Med. 2020;56(3):335–338. doi: 10.23736/s1973-9087.20.06292-9.
    1. Kortebein P, Frontera W, DeLisa J, JR B. Delisa’s physical medicine and rehabilitation: principals and practice. Philadelphia, PA: Lippincott Williams & Wilkins; 2019. Physical inactivity: physiologic impairments and related clinical conditions.
    1. Doglietto F, Vezzoli M, Gheza F, et al. Factors associated with surgical mortality and complications among patients with and without coronavirus disease 2019 (COVID-19) in Italy. JAMA Surg. 2020;155(8):691–702. doi: 10.1001/jamasurg.2020.2713.
    1. COVIDSurgCollaborative. GlobalSurg-CovidSurg week: determining the optimum timing for surgery following SARS-CoV-2 infection. . Published 2020.
    1. Carod-Artal FJ. Neurological complications of coronavirus and COVID-19. Rev Neurol. 2020;70(9):311–322. doi: 10.33588/rn.7009.2020179.
    1. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–690. doi: 10.1001/jamaneurol.2020.1127.
    1. Jin M, Tong Q. Rhabdomyolysis as potential late complication associated with COVID-19. Emerg Infect Dis. 2020;26(7):1618–1620. doi: 10.3201/eid2607.200445.
    1. Borku Uysal B, Ikitimur H, Yavuzer S, Islamoglu MS, Cengiz M. Case report: a COVID-19 patient presenting with mild rhabdomyolysis. Am J Trop Med Hyg. 2020;103(2):847–850. doi: 10.4269/ajtmh.20-0583.
    1. Zhang Q, Shan KS, Minalyan A. A rare presentation of coronavirus disease 2019 (COVID-19) induced viral myositis with subsequent rhabdomyolysis. Cureus. 2020;12(5):e8074. .
    1. Dolhnikoff M, Ferreira Ferranti J, de Almeida Monteiro RA, et al. SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome. Lancet Child Adolesc Heal. 2020;0(0). 10.1016/S2352-4642(20)30257-1.
    1. Ferrandi PJ, Alway SE, Mohamed JS. The interaction between SARS-CoV-2 and ACE2 may have consequences for skeletal muscle viral susceptibility and myopathies. J Appl Physiol. 2020. 10.1152/japplphysiol.00321.2020.
    1. Disser NP, De Micheli AJ, Schonk MM, et al. Musculoskeletal consequences of COVID-19. JBJS. 2020;102(14):1197-1204. .
    1. Leung TW, Wong KS, Hui AC, et al. Myopathic changes associated with severe acute respiratory syndrome: a postmortem case series. Arch Neurol. 2005;62(7):1113–1117. doi: 10.1001/archneur.62.7.1113.
    1. Lau HM-C, Lee EW-C, Wong CN-C, Ng GY-F, Jones AY-M, Hui DS-C. The impact of severe acute respiratory syndrome on the physical profile and quality of life. Arch Phys Med Rehabil. 2005;86(6):1134–1140. doi: 10.1016/j.apmr.2004.09.025.
    1. Paneroni M, Simonelli C, Saleri M, et al. Muscle strength and physical performance in patients without previous disabilities recovering from COVID-19 pneumonia. Am J Phys Med & Rehabil. 2020. 10.1097/phm.0000000000001641.
    1. Silver JK. Prehabilitation may help mitigate an increase in COVID-19 peripandemic surgical morbidity and mortality. Am J Phys Med Rehabil. 2020;99(6):459–463. doi: 10.1097/PHM.0000000000001452.
    1. Silver JK. Prehabilitation could save lives in a pandemic. BMJ. 2020;369:m1386. doi: 10.1136/bmj.m1386.
    1. Klok FA, Boon GJAM, Barco S, et al. The post-COVID-19 functional status scale: a tool to measure functional status over time after COVID-19. Eur Respir J. 2020;56(1). 10.1183/13993003.01494-2020.
    1. Nakamura K, Nakano H, Naraba H, Mochizuki M, Hashimoto H. Early rehabilitation with dedicated use of belt-type electrical muscle stimulation for severe COVID-19 patients. Crit Care. 2020;24(1):342. doi: 10.1186/s13054-020-03080-5.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever